Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Teo, Zhi L ^a   Park, Daniel J ^a   Provenzano, Elena ^a   Chatfield, Catherine A ^a   Odefrey, Fabrice A ^a   Nguyen Dumont, Tu ^a   Dowty, James G ^a   Hopper, John L ^a   Winship, Ingrid ^a,b   Goldgar, David E ^c   Southey, Melissa C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BRCA1 PROTEIN; BRCA2 PROTEIN; CYSTEINE; DNA; GLYCINE; ONCOPROTEIN; PALB2 PROTEIN; THREONINE; UNCLASSIFIED DRUG; BRCA1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; AUSTRALIA AND NEW ZEALAND; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CLINICAL FEATURE; COMPUTER MODEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DNA EXTRACTION; FAMILIAL CANCER; FAMILY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INTRON; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MULTICENTER STUDY; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PREVALENCE; PROTEIN DEPLETION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SANGER SEQUENCING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; AGED; AUSTRALIA; BREAST TUMOR; EARLY DIAGNOSIS; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY;

ADULT; AGED; AUSTRALIA; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84874368165     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3392     Document Type: Article

References (71)

1. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. 10.1016/S0140-6736(10)60892-6, 20609467.
2. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790. 10.1200/JCO.2008.16.0812, 18591545.
3. Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol 2010, 4:174-191. 10.1016/j.molonc.2010.04.011, 20542480.
4. National Breast and Ovarian Cancer Centre Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals. Book Advice about familial aspects of breast cancer and epithelial ovarian cancer: A guide for health professionals 2010, National Breast and Ovarian Cancer Centre, National Breast and Ovarian Cancer Centre.
5. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lapinski R, Wolitzer AL, Whittemore AS, West D, Seminara D, Olson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Concannon P. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T > G and c.1066-6T > G (IVS10-6T > G) from the breast cancer family registry. Hum Mutat 2006, 27:1122-1128. 10.1002/humu.20415, 16958054.
6. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D; Breast CS, Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622.
7. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, et al. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002, 31:55-59. 10.1038/ng879, 11967536.
8. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D; Breast CS, Easton DF, Stratton MR. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668.
9. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003, 72:1117-1130. 10.1086/375033, 1180265, 12677558.
10. Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, Terry MB, Daly MJ, Buys SM, Southey MC, Andrulis I, John EM, , , Khanna KK, Hopper JL, Oefner PJ, Lakhani S, Chenevix-Trench G. BCFR, kConFab Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2011, 13:R73. 10.1186/bcr2919, 3236337, 21787400, BCFR, kConFab.
11. Byrnes GB, Southey MC, Hopper JL. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?. Breast Cancer Res 2008, 10:208. 10.1186/bcr2099, 2481495, 18557994.
12. Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, Pylkäs K, Southey MC, Holli K, Kallioniemi A, Jukkola-Vuorinen A, Kataja V, Kosma VM, Xia B, Livingston DM, Winqvist R, Hopper JL. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 2008, 14:4667-4671. 10.1158/1078-0432.CCR-08-0210, 18628482.
13. Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian N, Apicella C, Byrnes GB, Winship I, Baglietto L, Giles GG, Goldgar DE, Foulkes WD, Hopper JL; kConFab FTBC. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 2010, 12:R109. 10.1186/bcr2796, 3046454, 21182766.
14. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu JM, Christ N, Liu XG, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Molecular Cell 2006, 22:719-729. 10.1016/j.molcel.2006.05.022, 16793542.
15. Sy SMH, Huen MSY, Chen JJ. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009, 106:7155-7160. 10.1073/pnas.0811159106, 2678481, 19369211.
16. Zhang F, Ma JL, Wu JX, Ye L, Cai H, Xia B, Yu XC. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Current Biology 2009, 19:524-529. 10.1016/j.cub.2009.02.018, 2750839, 19268590.
17. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164. 10.1038/ng1947, 17200671.
18. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007, 39:159-161. 10.1038/ng1942, 17200672.
19. Mann GJ, Thorne H, Balleine RL, Butow PN, Clarke CL, Edkins E, Evans GM, Fereday S, Haan E, Gattas M, Giles GG, Goldblatt J, Hopper JL, Kirk J, Leary JA, Lindeman G, Niedermayr E, Phillips KA, Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K, Chenevix-Trench G; Kathleen CC. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res 2006, 8:R12. 10.1186/bcr1377, 1413975, 16507150.
20. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O'Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D; Breast CFR. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004, 6:R375-R389. 10.1186/bcr801, 468645, 15217505.
21. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev in Oncol Hematol 1999, 31:209-223.
22. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, , American Society of Clinical Oncology, College of American Pathologists American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. American Society of Clinical Oncology, College of American Pathologists.
23. SIFT. , http://sift.jcvi.org/
24. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1082. 10.1038/nprot.2009.86, 19561590.
25. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814. 10.1093/nar/gkg509, 168916, 12824425.
26. Align GVGD. , http://agvgd.iarc.fr/
27. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006, 43:295-305. 2563222, 16014699.
28. Mathe E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 2006, 34:1317-1325. 10.1093/nar/gkj518, 1390679, 16522644.
29. Tavtigian SV, Byrnes GB, Goldgar DE, Thomas A. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. Hum Mutat 2008, 29:1342-1354. 10.1002/humu.20896, 18951461.
30. PolyPhen-2: prediction of functional effects of human nsSNPs. , http://genetics.bwh.harvard.edu/pph2/
31. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249. 10.1038/nmeth0410-248, 2855889, 20354512.
32. Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallée MP, Tavtigian SV, Concannon P, Foulkes WD, Bernstein L; WECARE SC, Bernstein JL, Begg CB. Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat 2012, 33:674-680. 10.1002/humu.22022, 22241545.
33. Southey MC, Tesoriero A, Young MA, Holloway AJ, Jenkins MA, Whitty J, Misfud S, McLachlan SA, Venter DJ, Armes JE. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. Hum Mutat 2003, 22:86-91. 10.1002/humu.10224, 12815598.
34. Bateman JF, Freddi S, Lamande SR, Byers P, Nasioulas S, Douglas J, Otway R, Kohonen-Corish M, Edkins E, Forrest S. Reliable and sensitive detection of premature termination mutations using a protein truncation test designed to overcome problems of nonsense-mediated mRNA instability (vol 13, pg 311, 1998). Hum Mutat 1999, 14:86-86.
35. NCBI. , http://www.ncbi.nlm.nih.gov/
36. e!Ensembl. , http://asia.ensembl.org/index.html
37. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 2008, 29:1327-1336. 10.1002/humu.20892, 3431198, 18951440.
38. Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011, 71:2222-2229. 10.1158/0008-5472.CAN-10-3958, 3059378, 21285249.
39. Wong MW, Nordfors C, Mossman D, Pecenpetelovska G, Avery-Kiejda KA, Talseth-Palmer B, Bowden NA, Scott RJ. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat 2011, 127:853-859. 10.1007/s10549-011-1443-0, 21409391.
40. Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Niederacher D, Arnold N, Meindl A. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat 2011, 32:E2176-E2188. 10.1002/humu.21478, 21618343.
41. Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, Dietz HC. Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum Mol Genet 2001, 10:99-105. 10.1093/hmg/10.2.99, 11152657.
42. Mendell JT, Medghalchi SM, Lake RG, Noensie EN, Dietz HC. Novel Upf2p orthologues suggest a functional link between translation initiation and nonsense surveillance complexes. Mol Cell Biol 2000, 20:8944-8957. 10.1128/MCB.20.23.8944-8957.2000, 86549, 11073994.
43. Le Hir H, Gatfield D, Izaurralde E, Moore MJ. The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. Embo J 2001, 20:4987-4997. 10.1093/emboj/20.17.4987, 125616, 11532962.
44. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. Embo J 2000, 19:6860-6869. 10.1093/emboj/19.24.6860, 305905, 11118221.
45. Durand C, Roeth R, Dweep H, Vlatkovic I, Decker E, Schneider KU, Rappold G. Alternative splicing and nonsense-mediated RNA decay contribute to the regulation of SHOX expression. PLoS One 2011, 6:e18115. 10.1371/journal.pone.0018115, 3063249, 21448463.
46. Grandemange S, Soler S, Touitou I. Expression of the familial Mediterranean fever gene is regulated by nonsense-mediated decay dagger. Hum Mol Genet 2009, 18:4746-4755. 10.1093/hmg/ddp437, 19755381.
47. Danckwardt S, Neu-Yilik G, Thermann R, Frede U, Hentze MW, Kulozik AE. Abnormally spliced beta-globin mRNAs: a single point mutation generates transcripts sensitive and insensitive to nonsense-mediated mRNA decay. Blood 2002, 99:1811-1816. 10.1182/blood.V99.5.1811, 11861299.
48. Amrani N, Sachs MS, Jacobson A. Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol 2006, 7:415-425.
49. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. A faux 3 '-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 2004, 432:112-118. 10.1038/nature03060, 15525991.
50. Hogg JR, Goff SP. Upf1 senses 3 ' UTR length to potentiate mRNA decay. Cell 2010, 143:379-389. 10.1016/j.cell.2010.10.005, 2981159, 21029861.
51. Eberle AB, Stalder L, Mathys H, Orozco RZ, Muhlemann O. Posttranscriptional gene regulation by spatial rearrangement of the 3 ' untranslated region. PLoS Biol 2008, 6:849-859.
52. Ivanov PV, Gehring NH, Kunz JB, Hentze MW, Kulozik AE. Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. Embo J 2008, 27:736-747. 10.1038/emboj.2008.17, 2265754, 18256688.
53. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment of BRCA2 by PALB2. Embo Rep 2009, 10:990-996. 10.1038/embor.2009.126, 2750052, 19609323.
54. Sy SMH, Huen MSY, Zhu YY, Chen JJ. PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem 2009, 284:18302-18310. 10.1074/jbc.M109.016717, 2709360, 19423707.
55. Sy SMH, Huen MSY, Chen JJ. MRG15 Is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem 2009, 284:21127-21131. 10.1074/jbc.C109.023937, 2755835, 19553677.
56. Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol 2010, 17:1255-1259. 10.1038/nsmb.1916, 2950913, 20871616.
57. Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J, Andreassen PR. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J Cell Sci 2010, 123:1124-1130. 10.1242/jcs.060178, 2844321, 20332121.
58. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, Kinzler KW, Vogelstein B, Eshleman JR, Goggins M, Klein AP. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217. 10.1126/science.1171202, 2684332, 19264984.
59. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, Bartsch DK. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010, 78:490-494. 10.1111/j.1399-0004.2010.01425.x, 20412113.
60. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A, Holter S, Rothenmund H, Ghadirian P, Foulkes WD, Gallinger S. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009, 137:1183-1186. 10.1053/j.gastro.2009.06.055, 19635604.
61. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 2010, 11:20. 2829009, 20122277.
62. Prokofyeva D, Bogdanova N, Bermisheva M, Zinnatullina G, Hillemanns P, Khusnutdinova E, Dork T. Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. Clin Genet 2012, 82:100-101. 10.1111/j.1399-0004.2011.01824.x, 22310028.
63. García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldés T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MI, San Román C, Robles-Díaz L, Urioste M, Benítez J. Analysis of FANCB and FANCN/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 2009, 113:545-551. 10.1007/s10549-008-9945-0, 18302019.
64. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010, 70:7353-7359. 10.1158/0008-5472.CAN-10-1012, 2948578, 20858716.
65. Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomaki K, Blomqvist C, Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 2009, 15:3214-3222. 10.1158/1078-0432.CCR-08-3128, 19383810.
66. Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet 2009, 76:421-426. 10.1111/j.1399-0004.2009.01277.x, 19863560.
67. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Boghossian L, Miron PL, Nathanson KL, Tung N. PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 2011, 10:225-231. 10.1007/s10689-011-9426-1, 21365267.
68. Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, Palli D. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer 2010, 9:181-185. 10.1007/s10689-009-9295-z, 19763884.
69. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di GH, Shen KW, Wu J, Lu JS, Luo JM, Yuan WT, Shen ZZ, Huang W, Shao ZM. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 2009, 114:457-462. 10.1007/s10549-008-0036-z, 18446436.
70. Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, Christiansen H, Rave-Frank M, Dork T, Imyanitov EN. PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat 2011, 126:545-550. 10.1007/s10549-010-1290-4, 3291835, 21165770.
71. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319. 10.1038/nature05609, 17287723.